![Riefberg_Vivian_Web_newsandnotes_1.jpg Riefberg_Vivian_Web_newsandnotes_1.jpg](/sites/default/files/styles/scale_1600w/public/json_node_import/Riefberg_Vivian_Web_newsandnotes_1.jpg?itok=O0dYQEki)
Foundation Professor weighs in on the Novavax COVID-19 vaccine
June 8, 2022
Vivian Riefberg, the David C. Walentas Jefferson Scholars Foundation Professor at U.Va.’s Darden School of Business, weighs in on the possible approval of Novavax’s fourth COVID-19 vaccine shot. Vivian is a retired senior partner with McKinsey & Company and has written extensively on government productivity and improving U.S. healthcare.